CD9 and cancer: Finally, we also found that halting the cell cycle with dinaciclib in two cancer cell lines, SH-SY5Y and HT29 (human colorectal adenocarcinoma-derived), dominantly suppresses the release of CD9+ sEVs, suggesting the broad relevance of our biological findings (Fig. 5f).